U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H16N8O
Molecular Weight 372.3833
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-04217903

SMILES

OCCN1C=C(C=N1)C2=CN=C3N=NN(CC4=CC=C5N=CC=CC5=C4)C3=N2

InChI

InChIKey=PDMUGYOXRHVNMO-UHFFFAOYSA-N
InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2

HIDE SMILES / InChI

Molecular Formula C19H16N8O
Molecular Weight 372.3833
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901

PF-04217903 is a triazolopyrazine inhibitor of c-MET that displays anticancer chemotherapeutic and anti-metastatic activities. PF-04217903 inhibits cell proliferation, invasion, and migration as well as tumor growth in various cancer models. In animal models of pancreatic neuroendocrine tumors, this compound prevents lymph node metastasis. PF-04217903 had been in phase I clinical trials by Pfizer for the treatment of solid tumors. In 2011, the company discontinued the development of the compound.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.8 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.24 μg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.81 μg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.6 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
16.4%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg single, oral
Studied dose
Dose: 30 mg
Route: oral
Route: single
Dose: 30 mg
Sources: Page: p.386
healthy, ADULT
n = 6
Health Status: healthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Population Size: 6
Sources: Page: p.386
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Route of Administration: Oral
Treatment with 100 nM of PF-04217903 for 4 hours resulted in decreased p-MET, pERK, p-AKT and p-PLCγ1 in mouse melanocytes expressing TRIM4-MET or ZKSCAN1-MET
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:37:56 UTC 2023
Edited
by admin
on Sat Dec 16 01:37:56 UTC 2023
Record UNII
CYJ9ATV1IJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-04217903
Common Name English
PF-4217903
Code English
2-(4-(1-(QUINOLIN-6-YLMETHYL)-1H-(1,2,3)TRIAZOLO(4,5-B)PYRAZIN-6-YL)-1H-PYRAZOL-1-YL)ETHANOL
Systematic Name English
1H-PYRAZOLE-1-ETHANOL, 4-(1-(6-QUINOLINYLMETHYL)-1H-1,2,3-TRIAZOLO(4,5-B)PYRAZIN-6-YL)
Systematic Name English
MET TYROSINE KINASE INHIBITOR PF-04217903
Code English
Classification Tree Code System Code
NCI_THESAURUS C143099
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
Code System Code Type Description
CAS
956905-27-4
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
PUBCHEM
17754438
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
DRUG BANK
DB12848
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
FDA UNII
CYJ9ATV1IJ
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
EPA CompTox
DTXSID401026097
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
SMS_ID
300000041325
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
ChEMBL
CHEMBL2001019
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
NCI_THESAURUS
C78483
Created by admin on Sat Dec 16 01:37:56 UTC 2023 , Edited by admin on Sat Dec 16 01:37:56 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
OFF TARGET->WEAK INHIBITOR
IC50
SALT/SOLVATE -> PARENT
OFF TARGET->WEAK INHIBITOR
No cardiac toxicity seen in clinical trials
IC50
OFF TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
Ki
Related Record Type Details
ACTIVE MOIETY